Clinical Scorecard: New Tiespectus Data in Treatment-Naïve nAMD
At a Glance
| Category | Detail |
|---|---|
| Condition | wet age-related macular degeneration (AMD) |
| Key Mechanisms | Blocks anti-VEGF and activates the Tie2 pathway |
| Target Population | Treatment-naïve eyes with wet AMD |
| Care Setting | Phase 2 clinical trial |
Key Highlights
- Tiespectus showed immediate and robust improvements in visual acuity.
- Average gain of 5 letters in visual acuity at week 1, improving to over 7 letters by week 12.
- Significant reduction in retinal thickness by over 215 µm by week 12.
- No ocular adverse events related to the drug were reported.
- Phase 3 clinical trial is currently underway.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
20 eyes with treatment-naïve AMD
Investigated 7 mg and 10 mg doses with three initial monthly doses.
Clinical Best Practices
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.